NDC product
Sunlenca
NDC 61958-3001 · Gilead Sciences, Inc.
Key facts
| Product NDC | 61958-3001 |
|---|---|
| Proprietary name | Sunlenca |
| Nonproprietary name | LENACAPAVIR SODIUM |
| Substances | LENACAPAVIR SODIUM |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Gilead Sciences, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA215974 |
| Pharmacologic classes | Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], HIV Capsid Inhibitors [MoA], Human Immunodeficiency Virus 1 Capsid Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA] |
| Marketing start | Dec 22, 2022 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: